

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL	
OMB Number:	3235-0076
Estimated average burden hours per response:	4.00

1. Issuer's Identity

CIK (Filer ID Number)	Previous Names	None	Entity Type
0001583648	Marika Inc.		X Corporation
Name of Issuer			Limited Partnership
PIERIS PHARMACEUTICALS, INC.			Limited Liability Company
Jurisdiction of Incorporation/Organization			General Partnership
NEVADA			Business Trust
Year of Incorporation/Organization			Other (Specify)
Over Five Years Ago			
X Within Last Five Years (Specify Year) 2013			
Yet to Be Formed			

2. Principal Place of Business and Contact Information

Name of Issuer			
PIERIS PHARMACEUTICALS, INC.			
Street Address 1		Street Address 2	
30 Lise-Meitner-Strasse			
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
Freising-Weihenstephan	GERMANY	85354	4.90816E+13

3. Related Persons

Last Name	First Name	Middle Name
Yoder	Stephen	S.
Street Address 1	Street Address 2	
c/o Pieris Pharmaceuticals, Inc.,	30 Lise-Meitner-Strasse	
City	State/Province/Country	ZIP/PostalCode
Freising-Weihenstephan	GERMANY	85354
Relationship: X Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

Chief Executive Officer and President

Last Name	First Name	Middle Name
Deptula-Hicks	Darlene	M.
Street Address 1	Street Address 2	
c/o Pieris Pharmaceuticals, Inc. ,	30 Lise-Metner-Strasse	
City	State/Province/Country	ZIP/PostalCode
Freising-Weihenstephan	GERMANY	85354
Relationship: X Executive Officer Director Promoter		

Clarification of Response (if Necessary):

Acting Chief Financial Officer

Last Name	First Name	Middle Name
Khuong	Chau	
Street Address 1	Street Address 2	
c/o Pieris Pharmaceuticals, Inc. ,	30 Lise-Metner-Strasse	
City	State/Province/Country	ZIP/PostalCode
Freising-Weihenstephan	GERMANY	85354
Relationship: Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

Chairman of the Board of Directors

Last Name	First Name	Middle Name
Takke	Christina	
Street Address 1	Street Address 2	
c/o Pieris Pharmaceuticals, Inc. ,	30 Lise-Metner-Strasse	
City	State/Province/Country	ZIP/PostalCode
Freising-Weihenstephan	GERMANY	85354
Relationship: Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Richman	Michael	
Street Address 1	Street Address 2	
c/o Pieris Pharmaceuticals, Inc. ,	30 Lise-Metner-Strasse	
City	State/Province/Country	ZIP/PostalCode
Freising-Weihenstephan	GERMANY	85354
Relationship: Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Prelack	Steven	
Street Address 1	Street Address 2	
c/o Pieris Pharmaceuticals, Inc. ,	30 Lise-Metner-Strasse	
City	State/Province/Country	ZIP/PostalCode
Freising-Weihenstephan	GERMANY	85354
Relationship: Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

4. Industry Group

Agriculture	Health Care	Retailing
Banking & Financial Services	Biotechnology	Restaurants
Commercial Banking	Health Insurance	Technology
Insurance	Hospitals & Physicians	Computers
Investing	X Pharmaceuticals	Telecommunications
Investment Banking	Other Health Care	Other Technology
Pooled Investment Fund		
Is the issuer registered as an investment company under	Manufacturing	Travel
	Real Estate	Airlines & Airports

the Investment Company Act of 1940?
 Yes No
 Other Banking & Financial Services
 Business Services
 Energy
 Coal Mining
 Electric Utilities
 Energy Conservation
 Environmental Services
 Oil & Gas
 Other Energy

Commercial
 Construction
 REITS & Finance
 Residential
 Other Real Estate

Lodging & Conventions
 Tourism & Travel Services
 Other Travel
 Other

5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)
Rule 504 (b)(1)(iii)	Section 3(c)(4)	Section 3(c)(12)
Rule 505	Section 3(c)(5)	Section 3(c)(13)
X Rule 506(b)	Section 3(c)(6)	Section 3(c)(14)
Rule 506(c)	Section 3(c)(7)	
Securities Act Section 4(a)(5)		

7. Type of Filing

X New Notice Date of First Sale 2014-12-17 First Sale Yet to Occur
 Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity	Pooled Investment Fund Interests
Debt	Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$2,000 USD

12. Sales Compensation

Recipient	Recipient CRD Number <input checked="" type="checkbox"/> None
Northland Securities, Inc.	None
(Associated) Broker or Dealer <input type="checkbox"/> None	(Associated) Broker or Dealer CRD Number <input type="checkbox"/> None
Trout Capital LLC	131589

Street Address 1

Street Address 2

45 S. 7th Street, Suite 2000

City	State/Province/Country	ZIP/Postal Code
Minneapolis	MINNESOTA	55402

State(s) of Solicitation (select all that apply) All States Foreign/non-US
 Check "All States" or check individual States

Recipient	Recipient CRD Number <input type="checkbox"/> None
Katalyst Securities LLC	112494
(Associated) Broker or Dealer <input type="checkbox"/> None	(Associated) Broker or Dealer CRD Number <input type="checkbox"/> None
American Portfolios Financial Services, Inc.	18487

Street Address 1

Street Address 2

15 Maiden Lane, Room 601

City	State/Province/Country	ZIP/Postal Code
New York	NEW YORK	10038

State(s) of Solicitation (select all that apply) All States Foreign/non-US
 Check "All States" or check individual States

- | |
|----------------|
| ARIZONA |
| CALIFORNIA |
| COLORADO |
| CONNECTICUT |
| FLORIDA |
| INDIANA |
| IOWA |
| MARYLAND |
| MASSACHUSETTS |
| MICHIGAN |
| MINNESOTA |
| NEW YORK |
| NORTH CAROLINA |
| OHIO |
| PENNSYLVANIA |
| TEXAS |
| VIRGINIA |

Recipient	Recipient CRD Number <input type="checkbox"/> None
Katalyst Securities LLC	112494

(Associated) Broker or Dealer None

(Associated) Broker or Dealer CRD Number None

Dinosaur Securities, L.L.C.

104446

Street Address 1

Street Address 2

470 Park Avenue South

9th Floor

City

State/Province/Country

ZIP/Postal Code

New York

NEW YORK

10016

State(s) of Solicitation (select all that apply)

Check "All States" or check individual States

All States

Foreign/non-US

ARIZONA
CALIFORNIA
COLORADO
CONNECTICUT
FLORIDA
INDIANA
IOWA
MARYLAND
MASSACHUSETTS
MICHIGAN
MINNESOTA
NEW YORK
NORTH CAROLINA
OHIO
PENNSYLVANIA
TEXAS
VIRGINIA

13. Offering and Sales Amounts

Total Offering Amount \$13,559,020 USD or Indefinite

Total Amount Sold \$13,559,020 USD

Total Remaining to be Sold \$0 USD or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

139

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$1,024,671 USD X Estimate

Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

Two placement agents and their designees received (i) cash commissions in the aggregate of up to 8% of the offerings gross proceeds and (ii) five-year warrants to purchase an aggregate of 8% of the number of shares sold in the offering.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
PIERIS PHARMACEUTICALS, INC.	/s/ Darlene M. Deptula-Hicks	Darlene Deptula-Hicks	Acting Chief Financial Officer	2014-12-31

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.